Becton, Dickinson And Company (NYSE:BDX)

WEB NEWS

Friday, July 31, 2009

Comments & Business Outlook

"We are pleased with our solid third quarter performance and, in particular, the results achieved by our Diagnostics segment and our Medical segment's Pharmaceutical Systems and Diabetes Care units," stated Edward J. Ludwig, Chairman and Chief Executive Officer. "In the face of a challenging global economy, we exceeded our overall expectations in the quarter and, as a result, we are revising our revenue and earnings guidance to the high end of the range previously provided for this year. We remain confident that our focus on productivity improvements and disciplined expense management, along with our ongoing investments in long-term growth opportunities, will ensure BD's future success." 

FULL YEAR 2009 Guidance Ending September a


  Full Year 2009 Guidance Full Year 2008 Reported Period Change
GAAP EPS  $4.95 to $5.00 $4.46 11% to 12%

Source: See Release, July 30, 2009

a The above forecasts reflect the Company's current and preliminary views and are therefore subject to change. Please refer to the Company's Safe Harbor Statement (usually in press releases) for the factors that could cause actual results to differ materially from those contained in any forward-looking statement.



Wednesday, July 1, 2009

Comments & Business Outlook

'In the face of global economic pressures, we are pleased to have achieved top-line growth in all three segments after adjusting for the negative impact of foreign currency translation. This growth, along with our continued focus on disciplined expense and currency risk management, has enabled us to deliver adjusted earnings in line with our expectations,' stated Edward J. Ludwig, Chairman and Chief Executive Officer. 'Our strong performance for the first half of fiscal 2009, combined with our commitment to continue to drive efficiency throughout BD, gives us the confidence to reaffirm our guidance for full-year adjusted earnings.'

Source: PR Newswire (April 28, 2009)


Thursday, January 29, 2009

Comments & Business Outlook

Guidance Report:

2009 Fiscal Full Year Guidance

2009 Guidance 2008 EPS Implied EPS Growth Rate
$4.95 $4.46 9% to 11%

"BD is off to a solid start to fiscal 2009. In particular, we continue to see strength in our Biosciences and Diagnostics segments and strong sales of insulin delivery products," said Edward J. Ludwig, Chairman and Chief Executive Officer. "In addition, our strong earnings per share growth has given us the confidence to raise guidance for fiscal 2009."

Source: PR Newswire (January 28, 2009)



Market Data powered by QuoteMedia. Terms of Use